These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31727505)

  • 1. Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming.
    McEntee CP; Moran HBT; Muñoz-Wolf N; Liddicoat AM; Carroll EC; Erbo-Wern J; Coulter IS; Andersen P; Follmann F; Lavelle EC
    Vaccine; 2020 Jan; 38(3):635-643. PubMed ID: 31727505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes.
    Igietseme JU; Murdin A
    Infect Immun; 2000 Dec; 68(12):6798-806. PubMed ID: 11083798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs.
    Bøje S; Olsen AW; Erneholm K; Agerholm JS; Jungersen G; Andersen P; Follmann F
    Immunol Cell Biol; 2016 Feb; 94(2):185-95. PubMed ID: 26268662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.
    Hansen J; Jensen KT; Follmann F; Agger EM; Theisen M; Andersen P
    J Infect Dis; 2008 Sep; 198(5):758-67. PubMed ID: 18652549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge.
    Pal S; Tifrea DF; Follmann F; Andersen P; de la Maza LM
    Vaccine; 2017 Mar; 35(13):1705-1711. PubMed ID: 28238632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA.
    Blakney AK; McKay PF; Christensen D; Yus BI; Aldon Y; Follmann F; Shattock RJ
    J Control Release; 2019 Jun; 304():65-74. PubMed ID: 31071377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.
    Pal S; Luke CJ; Barbour AG; Peterson EM; de la Maza LM
    Vaccine; 2003 Mar; 21(13-14):1455-65. PubMed ID: 12615442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
    Hadad R; Marks E; Kalbina I; Schön K; Unemo M; Lycke N; Strid Å; Andersson S
    APMIS; 2016 Dec; 124(12):1078-1086. PubMed ID: 27859689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.
    Yu H; Karunakaran KP; Jiang X; Shen C; Andersen P; Brunham RC
    Infect Immun; 2012 Apr; 80(4):1510-8. PubMed ID: 22290151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis.
    Tifrea DF; Ralli-Jain P; Pal S; de la Maza LM
    Infect Immun; 2013 May; 81(5):1741-50. PubMed ID: 23478318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.
    Karunakaran KP; Yu H; Jiang X; Chan Q; Moon KM; Foster LJ; Brunham RC
    Vaccine; 2015 Apr; 33(18):2159-66. PubMed ID: 25738816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
    Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
    Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.
    Dixit S; Singh SR; Yilma AN; Agee RD; Taha M; Dennis VA
    Nanomedicine; 2014 Aug; 10(6):1311-21. PubMed ID: 24602605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice.
    Paes W; Brown N; Brzozowski AM; Coler R; Reed S; Carter D; Bland M; Kaye PM; Lacey CJN
    Vaccine; 2016 Jul; 34(35):4123-4131. PubMed ID: 27389169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis.
    Eko FO; Lubitz W; McMillan L; Ramey K; Moore TT; Ananaba GA; Lyn D; Black CM; Igietseme JU
    Vaccine; 2003 Apr; 21(15):1694-703. PubMed ID: 12639492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM-CSF transgene-based adjuvant allows the establishment of protective mucosal immunity following vaccination with inactivated Chlamydia trachomatis.
    Lu H; Xing Z; Brunham RC
    J Immunol; 2002 Dec; 169(11):6324-31. PubMed ID: 12444139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.
    Pal S; Theodor I; Peterson EM; de la Maza LM
    Infect Immun; 2001 Oct; 69(10):6240-7. PubMed ID: 11553566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulation of Recombinant MOMP in Extended-Releasing PLGA 85:15 Nanoparticles Confer Protective Immunity Against a
    Sahu R; Dixit S; Verma R; Duncan SA; Smith L; Giambartolomei GH; Singh SR; Dennis VA
    Front Immunol; 2021; 12():660932. PubMed ID: 33936096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.